FDA approved combination clearances for Elanco's Experior use on June 27, 2025.
3 reports, 2 independent
Updated Wed 00:00
Still developing
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved combination clearances for Elanco's Experior use on June 27, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approved Elanco's Experior despite safety concerns, following CVM review.1 source
First confirmed screwworm case in Texas livestock; industry thanks FDA for preparation.1 source
- FDA grants combination clearance for Elanco's Experior.
Keep exploring
The entities involved
Related events
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Discussion on the limits of pharmacotherapy and the role of FDA approvals.
- Adam Craig reported positive results that could support FDA approval for a treatment.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
Coverage
Newest first; wire copies grouped- mesabitribune.com
- hpj.com
- Unknown outlet